Refine by
Congestive Heart Failure Articles & Analysis
28 news found
The appointments enable Hemostemix to sell VesCell™ in Florida to podiatrist and vascular surgeons, to treat PAD & CLTI; and to cardiologist to treat Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and Congestive Heart Failure. The additions to the leadership team are top-tier talent with a proven track record of success in ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
Digoxin is used primarily to improve the heart’s ability to pump blood in patients with congestive heart failure (CHF) and to treat problems such as high blood pressure. It is also used to help normalize certain heart arrhythmias (abnormal types of heartbeats). Another is the Anti-Fluorescien monoclonal ...
Most advanced in the clinic are investigational treatments for Parkinson’s disease, Pompe disease and congestive heart failure. Gene therapy programs for Huntington’s disease and multiple systems atrophy are currently enrolling patients into first-in-human studies. ...
ByBayer AG
The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure. AskBio’s gene therapy platform includes ...
ByBayer AG
Bodyport’s focus on the patient has driven them to create an incredibly simple solution for patients with congestive heart failure. The Bodyport solution will reduce common monitoring complexities for patients while advancing how clinicians manage their patients,” Pursley said. ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that a scientific session titled “Debating Volume-based versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure” was held during the Heart Failure Society of America ...
When people with congestive heart failure feel short of breath and fatigued, it means their lungs are slowly filling with fluid. ...
There might be some good news for the nearly six million Americans with congestive heart failure. Those patients are often in and out of hospitals because their lungs fill with fluid. ...
Congestive heart failure is one of the most common reasons elderly people end up in the hospital. ...
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart ...
BioVentrix, Inc., a privately held medical device company focused on less invasive therapies to treat the left ventricle (LV), known to be the root cause of congestive heart failure (CHF), today announced that it has acquired MateraCor, Inc., a company focused on preventing progression of, and reversing, heart ...
During diabetic foot ulcer episodes-of-care, individuals are 30 times more likely to have a lower limb amputation, eight times more likely to be hospitalized for peripheral vascular disorders, and about two times more likely to be hospitalized for renal failure, congestive heart failure (CHF), pulmonary edema, chronic obstructive ...
George Mark, a clinical cardiac electrophysiologist with The Heart House in Marlton, N.J., stated that “CCM is an important therapeutic option appropriate for patients who manifest lifestyle limiting symptoms despite guideline-directed medical therapy (GDMT) for congestive heart failure (CHF). ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. ...
” Chronic rhinosinusitis is one of the most common chronic medical conditions worldwide, affecting all age groups, with an estimated incidence of nearly 11% in Europe.i Of those in the UK with chronic sinusitis, approximately 15 percent undergo sinus surgery yearly after failing medical treatment.ii Quality of life scores of patients with chronic sinusitis are significantly lower than in ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter-based Ventricular Restoration (TCVR), today announced that Jim Dillon has been named President and CEO. ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter based Ventricular Restoration (TCVR), today announced that the German Institute for Hospital Remuneration (InEK) has renewed the NUB Status 1 reimbursement designation in Germany for the Revivent TC™ TransCatheter ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE ...